Form 4: Cytokinetics Director Nancy Wysenski Reports Stock Transactions
SEC Form 4 Filing
Director Nancy Wysenski reports acquisition of Cytokinetics stock and stock options.
Summary
- On May 15, 2024, Nancy Wysenski, a director of Cytokinetics Inc., reported transactions involving the company's stock.
- Wysenski acquired 5,600 shares of common stock at $0.
- Following the transaction, Wysenski directly owns 22,756 shares of Cytokinetics Inc.
- Wysenski also acquired 3,636 non-qualified stock options with an exercise price of $60.50, exercisable from June 17, 2024, and expiring on May 15, 2034.
- Following the transaction, Wysenski directly owns 3,636 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, which is common practice and regulated by the SEC to ensure transparency and prevent insider trading.
Key Dates
| Date | Description |
|---|---|
| 05/15/2024 | Date of stock and option transactions. |
| 05/15/2024 | Date of earliest transaction. |
| 06/17/2024 | Date the non-qualified stock options become exercisable. |
| 05/15/2034 | Expiration date of the non-qualified stock options. |
| 05/16/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.